Ablynx could be target after Medarex acquisition
This article was originally published in Scrip
Executive Summary
Ablynx, the Belgian biotech company that develops Nanobodies, might be an acquisition target for big pharma following Bristol-Myers Squibb's buyout of Medarex last week, according to Piper Jaffray.